London · Delayed Price · Currency is GBP · Price in GBX Hikma Pharmaceuticals Earnings Call Transcripts
Fiscal Year 2026
-
Performance is in line with expectations, with robust demand and reiterated 2026 guidance. Strategic focus includes exiting the 503B business, investing in R&D, and expanding capacity. Middle East demand is strong, inflation is managed, and biosimilars lead in MENA.
Fiscal Year 2025
-
CEO emphasized long-term growth, decentralization, and heavy R&D investment. Injectables face near-term margin pressure but are set for recovery post-2027, while Rx and MENA divisions drive current growth. $5B revenue target for 2030 remains on track.
-
Revenue grew 6% and core operating profit 3% in 2025, with strong Branded and Hikma Rx performance offsetting margin pressure in Injectables. 2026 guidance targets 2%-4% revenue growth, increased R&D spend, and margin stabilization, with over 250 product launches planned through 2029.
-
Guidance for 2024-2027 is revised to the lower end of revenue and EBIT growth ranges, with injectable margins now guided at 30% due to operational delays and higher R&D. Rx margins are set to approach 20% by 2026, supported by a strong pipeline and CMO growth.
-
Strong revenue growth across all segments, with injectables and branded divisions outperforming and robust R&D investment supporting future pipeline. Margins were impacted by FX and product mix, but guidance and long-term targets remain intact, with significant expansion in contract manufacturing and compounding expected.
-
Strong H1 2025 revenue growth was driven by new launches and the Xellia acquisition, though operating profit declined due to FX and mix effects. Full-year guidance is reiterated, with robust segmental performance and continued investment in capacity and R&D.
-
Strong revenue growth and robust demand across all segments support reiterated 2025 guidance, with profit growth expected in the second half due to contract manufacturing timing. U.S.-based manufacturing and high inventory levels provide resilience against tariff and supply chain uncertainties, while ongoing investments in capacity and R&D underpin future growth.
-
The event highlighted robust multi-year growth, strong margins, and a diversified business model across injectables, branded, and generics. Strategic investments in R&D, capacity, and acquisitions are driving expansion, with a focus on complex products and new market opportunities.
Fiscal Year 2024
-
Core revenue grew 10% in 2024, exceeding guidance, with strong performance across all segments and significant investments in R&D and manufacturing. Outlook for 2025 anticipates continued growth, increased R&D spend, and margin stability despite some headwinds.
-
FY24 results exceeded guidance, with double-digit growth in Injectables and Generics, and strong Branded performance. Strategic investments in R&D, capacity, and acquisitions like Xellia support a positive medium-term outlook, despite FX and pricing headwinds.
-
Ambitious growth in MENA is driven by a robust pipeline focused on chronic and specialty diseases, strong local manufacturing, and accelerated business development. Operational efficiency, stakeholder engagement, and strategic partnerships underpin margin expansion and market leadership.
-
Operating profit and revenue guidance are reiterated, with strong divisional performance and robust product pipelines. Contract manufacturing is set to expand significantly, supported by new deals and facility investments. R&D and branded business growth remain strategic priorities.
-
Delivered strong H1 results with 10% revenue growth and upgraded 2024 guidance. Injectables, Branded, and Generics all performed well, with significant investments in R&D, capacity, and M&A. Risks include increased competition and higher R&D costs in H2.
-
Group revenue grew 10% year-over-year, with strong branded and injectables performance and a flat core operating profit. Upgraded 2024 guidance projects 6%-8% revenue growth and $700-$730 million core operating profit, supported by robust cash flow and strategic investments.
-
The acquisition adds $75M in revenue, a robust pipeline, and significant US manufacturing and R&D capacity, supporting long-term growth and margin expansion. Integration includes a 2-year facility upgrade and transfer of key teams, with new products launching from 2025.